Introgen Invites You to Join Its Third Quarter Conference Call on the Web

Apr 26, 2001, 01:00 ET from Introgen Therapeutics, Inc.

    AUSTIN, Texas, April 26 /PRNewswire/ --
 Introgen Therapeutics, Inc. (Nasdaq: INGN), in conjunction with its third
 quarter financial results for the fiscal year ended June 30, 2001, press
 release, invites you to listen to its conference call that will be broadcast
 live over the Internet on May 1, 2001 at 4:30 p.m. EDT with David Nance,
 president and chief executive officer, Jim Albrecht, chief financial officer,
 James Merritt, M.D., vice president of clinical affairs, and Tom Finnegan,
 vice president of finance.
 
      What:     Introgen Therapeutics quarterly earnings conference call
 
      When:     May 1, 2001, 4:30 p.m. EDT
 
      Where:
      http://theater.talkpoint.com/audiocast/starthere.asp?evid=ingn05012001
 
      How:      Live over the Internet -- Simply log on to the Web at the
                address listed above or access through Introgen's Website
 
      Contact:  Emily Katz, Noonan/Russo Communications, 415-677-4455, ext. 282
 
     Introgen is a leader in the development and production of gene-based drugs
 for the treatment of cancer and other diseases.  Introgen's product candidates
 engage precise molecular targets to produce a highly specific therapeutic
 effect.  By selectively killing cancer cells and harnessing natural protection
 mechanisms, Introgen's product candidates may be less toxic than conventional
 treatments.  Introgen specializes in combining appropriate gene delivery
 systems and therapeutic genes to make its gene-based drugs.  Introgen's lead
 product candidate, INGN 201 (Adenoviral-p53), is currently in Phase III
 clinical trials for the treatment of head and neck cancer.  INGN 201 has been
 used in numerous clinical trials worldwide either alone or in combination with
 conventional treatments such as chemotherapy and radiotherapy.  Introgen is
 also conducting a Phase II clinical trial for INGN 201 in lung cancer, and
 Phase I trials using INGN 201 in additional cancer indications including
 prostate, ovarian, bladder, brain, and breast cancer.  INGN 241
 (Adenoviral-mda7) for the treatment of solid tumors in currently in Phase I
 clinical development.
     If you are unable to participate during the live web cast, the call will
 be archived for 30 days at:
 http://theater.talkpoint.com/audiocast/starthere.asp?evid=ingn05012001 or
 http://www.introgen.com at Investor Relations.
     Minimum Requirements to listen to broadcast: The RealPlayer software,
 downloadable free from http://www.real.com/products/player/index.html, and at
 least a 14.4Kbps connection to the Internet.  If you experience problems
 listening to the broadcast, send an email to webmaster@vdat.com.
 
     Contact:  Emily Katz of Noonan/Russo Communications, 415-677-4455,
 ext. 282, for Introgen Therapeutics, Inc.; or Channing Burke of Introgen
 Therapeutics, 512-708-9310, ext. 322.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X44687845
 
 

SOURCE Introgen Therapeutics, Inc.
    AUSTIN, Texas, April 26 /PRNewswire/ --
 Introgen Therapeutics, Inc. (Nasdaq: INGN), in conjunction with its third
 quarter financial results for the fiscal year ended June 30, 2001, press
 release, invites you to listen to its conference call that will be broadcast
 live over the Internet on May 1, 2001 at 4:30 p.m. EDT with David Nance,
 president and chief executive officer, Jim Albrecht, chief financial officer,
 James Merritt, M.D., vice president of clinical affairs, and Tom Finnegan,
 vice president of finance.
 
      What:     Introgen Therapeutics quarterly earnings conference call
 
      When:     May 1, 2001, 4:30 p.m. EDT
 
      Where:
      http://theater.talkpoint.com/audiocast/starthere.asp?evid=ingn05012001
 
      How:      Live over the Internet -- Simply log on to the Web at the
                address listed above or access through Introgen's Website
 
      Contact:  Emily Katz, Noonan/Russo Communications, 415-677-4455, ext. 282
 
     Introgen is a leader in the development and production of gene-based drugs
 for the treatment of cancer and other diseases.  Introgen's product candidates
 engage precise molecular targets to produce a highly specific therapeutic
 effect.  By selectively killing cancer cells and harnessing natural protection
 mechanisms, Introgen's product candidates may be less toxic than conventional
 treatments.  Introgen specializes in combining appropriate gene delivery
 systems and therapeutic genes to make its gene-based drugs.  Introgen's lead
 product candidate, INGN 201 (Adenoviral-p53), is currently in Phase III
 clinical trials for the treatment of head and neck cancer.  INGN 201 has been
 used in numerous clinical trials worldwide either alone or in combination with
 conventional treatments such as chemotherapy and radiotherapy.  Introgen is
 also conducting a Phase II clinical trial for INGN 201 in lung cancer, and
 Phase I trials using INGN 201 in additional cancer indications including
 prostate, ovarian, bladder, brain, and breast cancer.  INGN 241
 (Adenoviral-mda7) for the treatment of solid tumors in currently in Phase I
 clinical development.
     If you are unable to participate during the live web cast, the call will
 be archived for 30 days at:
 http://theater.talkpoint.com/audiocast/starthere.asp?evid=ingn05012001 or
 http://www.introgen.com at Investor Relations.
     Minimum Requirements to listen to broadcast: The RealPlayer software,
 downloadable free from http://www.real.com/products/player/index.html, and at
 least a 14.4Kbps connection to the Internet.  If you experience problems
 listening to the broadcast, send an email to webmaster@vdat.com.
 
     Contact:  Emily Katz of Noonan/Russo Communications, 415-677-4455,
 ext. 282, for Introgen Therapeutics, Inc.; or Channing Burke of Introgen
 Therapeutics, 512-708-9310, ext. 322.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X44687845
 
 SOURCE  Introgen Therapeutics, Inc.